RT Journal Article
SR Electronic
T1 Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.10.20067488
DO 10.1101/2020.07.10.20067488
A1 Lindsey Wu
A1 Julia Mwesigwa
A1 Muna Affara
A1 Mamadou Bah
A1 Simon Correa
A1 Tom Hall
A1 James G. Beeson
A1 Kevin K.A. Tetteh
A1 Immo Kleinschmidt
A1 Umberto D’Alessandro
A1 Chris Drakeley
YR 2020
UL http://medrxiv.org/content/early/2020/07/11/2020.07.10.20067488.abstract
AB Background As malaria transmission declines, sensitive diagnostics are needed to evaluate interventions and monitor transmission. Serological assays measuring malaria antibody responses offer a cost-effective detection method to supplement existing surveillance tools.Methods A prospective cohort study was conducted from 2013 to 2015 in 12 villages across five administrative regions in The Gambia. Serological analysis included samples from the West Coast Region at the start and end of the season (July and December 2013) and from the Upper River Region in July and December 2013, and April and December 2014. Antigen-specific antibody responses to eight Plasmodium falciparum (P.falciparum) antigens – Etramp5.Ag1, GEXP18, HSP40.Ag1, Rh2.2030, EBA175 RIII-V, PfMSP119, PfAMA1, PfGLURP.R2 - were quantified using a multiplexed bead-based assay. The association between antibody responses and clinical and parasitological endpoints was estimated at the individual, household, and population level.Results Strong associations were observed between clinical malaria and concurrent sero-positivity to Etramp5.Ag1 (aOR 4.60 95%CI 2.98 - 7.12), PfMSP119 (aOR 4.09 95%CI 2.60 - 6.44), PfAMA1 (aOR 2.32 95%CI 1.40 - 3.85) and PfGLURP.R2 (aOR 3.12, 95%CI 2.92 – 4.95), while asymptomatic infection was associated with sero-positivity to all antigens. Village-level sero-prevalence amongst children 2-10 years against Etramp5.Ag1, HSP40.Ag1, and PfMSP119 showed the highest correlations with clinical and P.falciparum infection incidence rates. For all antigens, there was increased odds of asymptomatic P.falciparum infection in subjects residing in a compound with greater than 50% sero-prevalence, with a 2- to 3-fold increase in odds of infection associated with Etramp5.Ag1, GEXP18, Rh2.2030, PfMSP119 and PfAMA1. For individuals residing in sero-positive compounds, the odds of clinical malaria were reduced, suggesting a protective effect.Conclusions At low transmission, long-lived antibody responses could indicate foci of malaria transmission that have been ongoing for several seasons or years. In settings where sub-patent infections are prevalent and fluctuate below the detection limit of polymerase chain reaction (PCR), the presence of short- lived antibodies may indicate recent infectivity, particularly in the dry season when clinical cases are rare. Serological responses may reflect a persistent reservoir of infection, warranting community- targeted interventions if individuals are not clinically apparent but have the potential to transmit. Therefore, serological surveillance at both the individual and household level may be used to target interventions where there are foci of asymptomatically infected individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the UK Medical Research Council (UKMRC) through the LSHTM Doctoral Training Programme studentship received by LW. The funders had no role in the design of the study, collection, analysis, interpretation of data or writing of the manuscript. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.aORAdjusted odds ratioCIConfidence intervalDBSDried blood spotEBA175Erythrocyte binding antigen 175Etramp5.Ag1Early transcribed membrane protein 5GEEGeneralised estimating equationsGEXP18Gametocyte export protein 18 (GEXP18)HSP40.Ag1Heat shock protein 40IgGImmunoglobulinLLINLong-lasting insecticide treated netMDAMass drug administration (MDA)MFIMedian fluorescence intensityPCDPassive case detectionPCRPolymerase chain reactionPf, P.falciparumPlasmodium falciparumPfAMA1P.falciparum apical membrane antigen 1PfMSP119P.falciparum merozoite surface antigen 1 19-kDa carboxy-terminal regionRDTRapid diagnostic testRh2.2030Reticulocyte binding protein homologue 2URRUpper River Region, The GambiaWCRWest Coast Region, The Gambia